Summary
- Today, we take an in-depth look at small-cap concern Eloxx Pharmaceuticals.
- The firm's pipeline seems to be making some progress against cystic fibrosis and has multiple 'shots on goal'.
- A full investment analysis is presented in the paragraphs below.
- Looking for a portfolio of ideas like this one? Members of The Biotech Forum get exclusive access to our model portfolio. Start your free trial today »
A kind of banalization of celebrity has occurred: we are now offered an instant, ready-to-mix fame as nutritious as packet soup." - J.G. Ballard, The Atrocity Exhibition
Today, we take a look at an 'off the radar' small-cap concern targeting the rare disease space.
Company Overview:
Eloxx Pharmaceuticals (ELOX) uplisted to the NASDAQ in 2018 and is a Waltham, Massachusetts based clinical stage biopharmaceutical company that is developing novel RNA-modulating drug candidates, which are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. Thus, the company's development strategy is to target high-unmet need rare and ultra-rare nonsense mutation-afflicted patient populations. Eloxx's lead product candidate, ELX-02, is in clinical development for cystic fibrosis and cystinosis. Additionally, the company has a library of preclinical drug candidates that are designed to be eukaryotic ribosomal selective glycosides. Furthermore, the company has recently announced a new program focused on rare ocular genetic disorders. Eloxx Pharmaceuticals has a market capitalization of approximately $375 million and trades for roughly $9.50 a share.
Pipeline:
Source: Company Presentation
